Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles (2016 - 2026)

Ani Pharmaceuticals' Intangibles history spans 14 years, with the latest figure at $479.5 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 11.5% to $479.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $479.5 million, a 11.5% decrease, with the full-year FY2025 number at $479.5 million, down 11.5% from a year prior.
  • Intangibles hit $479.5 million in Q4 2025 for Ani Pharmaceuticals, down from $499.8 million in the prior quarter.
  • Over the last five years, Intangibles for ANIP hit a ceiling of $569.8 million in Q3 2024 and a floor of $4.3 million in Q2 2023.
  • Historically, Intangibles has averaged $291.5 million across 5 years, with a median of $245.2 million in 2022.
  • Biggest five-year swings in Intangibles: tumbled 98.41% in 2023 and later soared 4157.63% in 2024.
  • Tracing ANIP's Intangibles over 5 years: stood at $294.1 million in 2021, then fell by 14.45% to $251.6 million in 2022, then decreased by 16.94% to $209.0 million in 2023, then surged by 159.24% to $541.8 million in 2024, then fell by 11.5% to $479.5 million in 2025.
  • Business Quant data shows Intangibles for ANIP at $479.5 million in Q4 2025, $499.8 million in Q3 2025, and $15.8 million in Q2 2025.